Strong Balance Sheet / Low LeverageVery low leverage and a high equity ratio give Falco durable financial flexibility. This solidity supports capital spending, acquisitions, and dividend stability through cycles, and reduces refinancing risk—key for a healthcare services firm with steady long-term demand.

Operating Cash Generation QualityOperating cash flow materially exceeds accounting profits, indicating earnings are backed by cash. That sustained cash generation supports ongoing operations, working capital and service investments even if FCF lags, and signals resilient core cash conversion in diagnostics.

Stable Gross Margins And Improving Net MarginConsistent gross margins and an improving net margin point to durable cost control and pricing power in its clinical testing business. Margin stability helps protect earnings against volume swings and underpins the company's ability to fund R&D and maintain service quality.

Bears Say

Declining RevenueSustained top-line decline weakens scale economics in a service business where fixed costs and lab capacity matter. Continued revenue contraction can erode pricing leverage, reduce utilization of facilities, and limit reinvestment capacity over the medium term.

Declining Free Cash Flow / Cash RetentionA falling FCF growth rate and sub‑1.0 FCF/Net Income ratio imply the company retains less cash from profits. That reduces capacity to fund capex, acquisitions, or higher dividends without tapping reserves, challenging long-term investment flexibility despite strong OCF.

Erosion In EBIT / EBITDA MarginsTrailing declines in operating margins suggest rising cost pressure or mix shifts in testing services. Persistent margin erosion would compress returns on capital and limit ability to boost ROE, undermining profitability resilience in a competitive diagnostics market.

4671 FAQ

What was FALCO HOLDINGS Co., Ltd’s price range in the past 12 months?

FALCO HOLDINGS Co., Ltd lowest stock price was ¥2065.00 and its highest was ¥2775.00 in the past 12 months.

What is FALCO HOLDINGS Co., Ltd’s market cap?

FALCO HOLDINGS Co., Ltd’s market cap is ¥26.25B.

When is FALCO HOLDINGS Co., Ltd’s upcoming earnings report date?

FALCO HOLDINGS Co., Ltd’s upcoming earnings report date is May 08, 2026 which is in 56 days.

How were FALCO HOLDINGS Co., Ltd’s earnings last quarter?

FALCO HOLDINGS Co., Ltd released its earnings results on Feb 10, 2026. The company reported ¥60.64 earnings per share for the quarter, beating the consensus estimate of N/A by ¥60.64.

Is FALCO HOLDINGS Co., Ltd overvalued?

According to Wall Street analysts FALCO HOLDINGS Co., Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FALCO HOLDINGS Co., Ltd pay dividends?

FALCO HOLDINGS Co., Ltd pays a Semiannually dividend of ¥62.5 which represents an annual dividend yield of 4.81%. See more information on FALCO HOLDINGS Co., Ltd dividends here

What is FALCO HOLDINGS Co., Ltd’s EPS estimate?

FALCO HOLDINGS Co., Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FALCO HOLDINGS Co., Ltd have?

FALCO HOLDINGS Co., Ltd has 10,680,177 shares outstanding.

What happened to FALCO HOLDINGS Co., Ltd’s price movement after its last earnings report?

FALCO HOLDINGS Co., Ltd reported an EPS of ¥60.64 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.006%.

Which hedge fund is a major shareholder of FALCO HOLDINGS Co., Ltd?

Currently, no hedge funds are holding shares in JP:4671

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FALCO HOLDINGS Co., Ltd

FALCO HOLDINGS Co., Ltd., a medical service company, primarily provides clinical testing and dispensing pharmacy services to medical institutions and companies in Japan. It offers clinical testing services in the fields of genetic tests, biochemistry, hematology, pathology, immunology, microbiology, and radio immunoassay; genetic testing services; and genomic-based drug discovery and biotechnology drug development services. The company also provides medical information technology services; food sanitation and environmental testing services; and food related genetic testing services to food manufacturers, retailers, and restaurants. In addition, it is involved in the dispensing pharmacies and drugstores business; and development and sale of various medical information systems, including @home Dr. electronic medical charts for clinics with concentrated clinical testing, as well as TASCAL for ASP, a medical support system. The company was founded in 1962 and is headquartered in Kyoto, Japan.